Citius Pharmaceuticals, Inc. Receives a Complete Response Letter from the US Food and Drug Administration (FDA) for LYMPHIR™ (Denileukin Diftitox) for the Treatment of Patients with Relapsed or Refractory Cutaneous T Cell Lymphoma

By
Bob
-
0
241
Citius Pharmaceuticals, Inc. announced that the US FDA has issued a Complete Response Letter regarding the Company’s Biologics License Application seeking approval for denileukin diftitox.
[Citius Pharmaceuticals, Inc.]
Press Release